Cargando…
Higher Interrater Agreement of FDG-PET/CT than Bone Scintigraphy in Diagnosing Bone Recurrent Breast Cancer
The purpose was to investigate the interrater agreement of FDG-PET/CT and bone scintigraphy for diagnosing bone recurrence in breast cancer patients. A total of 100 women with suspected recurrence of breast cancer underwent planar whole-body bone scintigraphy with [99mTc]DPD and FDG-PET/CT. Scans we...
Autores principales: | Holm, Jorun, Ahangarani Farahani, Ziba, Gerke, Oke, Baun, Christina, Falch, Kirsten, Malene Grubbe, Hildebrandt |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760596/ https://www.ncbi.nlm.nih.gov/pubmed/33260766 http://dx.doi.org/10.3390/diagnostics10121021 |
Ejemplares similares
-
Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy
por: Hansen, Jeanette Ansholm, et al.
Publicado: (2021) -
Interrater Agreement and Reliability of PERCIST and Visual Assessment When Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer
por: Sørensen, Jonas S., et al.
Publicado: (2020) -
Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancer
por: Baun, Christina, et al.
Publicado: (2018) -
FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond
por: Hildebrandt, Malene Grubbe, et al.
Publicado: (2019) -
FDG-PET/CT Versus Contrast-Enhanced CT for Response Evaluation in Metastatic Breast Cancer: A Systematic Review
por: Helland, Fredrik, et al.
Publicado: (2019)